NASDAQ · BCRX
BioCryst Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BCRX: Nov 04, 2026
BioCryst Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.1. The reported EPS for the same quarter last year was $0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.10 | $0.15 | $0.06 | 4 |
| Dec 2026 | $0.11 | $0.18 | $0.06 | 3 |
| Mar 2027 | $0.10 | $0.11 | $0.09 | 2 |
| Jun 2027 | $0.14 | $0.15 | $0.13 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat- Zacks · Oct 29, 9:00 AM EDTPacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthPacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 29, 8:40 AM EDTIs AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
- Zacks · Oct 28, 9:00 AM EDTBioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseBioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 21, 8:03 AM EDTBioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And Older(RTTNews) – BioCryst Pharmaceuticals Inc. (BCRX) said Wednesday that the U.S. Food and Drug Administration has approved its oral pellet formulation of Orladeyo for preventing hereditary angioedema (HAE) attacks in individuals aged 12 and older.
- MarketBeat · Sep 18, 10:01 PM EDTBioCryst Eyes $1B Rare-Disease Future Through External InnovationModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItBioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executi
- Zacks · Sep 18, 12:31 PM EDT4 Biotech Stocks to Watch as Potential Takeover TargetsBiotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
- Zacks · Sep 15, 9:50 AM EDTPHVS Stock Rises 10% in a Month: What Is Driving the Rally?Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
- RTTNews · Sep 9, 6:51 AM EDTBioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook(RTTNews) – It's been nearly six years since BioCryst Pharmaceuticals Inc. (BCRX) launched its lead drug ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of hereditary angioedema attacks. Over this period, ORLADEYO has delivered steady
- MarketBeat · Sep 6, 8:50 AM EDTModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItDrug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug marke
- Zacks · Aug 31, 9:40 AM EDTIs BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- Zacks · Aug 28, 9:55 AM EDTWall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for BioCryst Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.